CDK2-IN-47

• Description :

  CDK2-IN-47 is a potent CDK2 inhibitor with an IC50 of 0.21 μM. CDK2-IN-47 exhibits outstanding anticancer activity against MCF-7, HCT-116, and MGC-803 cell lines. CDK2-IN-47 effectively induces G1 cell cycle arrest, retinoblastoma protein (Rb) dephosphorylation, and significant apoptosis. CDK2-IN-47 can be used for the studies of breast cancer, colorectal cancer and gastric cancer[1].

• UNSPSC :

  12352005

• Target :

  Apoptosis; CDK

• Related Pathways :

  Apoptosis; Cell Cycle/DNA Damage

• Field of Research :

  Cancer

• Smiles :

  O=C1C(C)=CN(CC(N[C@H](CC(C)C)C(OC)=O)=O)C2=NC(SC)=NN12

• Molecular Formula :

  C16H23N5O4S

• Molecular Weight :

  381.45

• References & Citations :

  [1]Nagy IM, et al. Design, synthesis, biological and computational evaluation of novel S/N-glycerolyl and peptide-conjugated [1,2,4]triazolo[1,5-a]pyrimidine derivatives as potent CDK2 inhibitors for anticancer therapy. Bioorg Chem. 2025 Sep 2;165:108952.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  CDK1; CDK2; CDK4; CDK6; CDK7; CDK9